The Carlyle Group has bolstered its healthcare investment capabilities with the acquisition of life sciences investment manager Abingworth, according to a report by AlternativesWatch.
Financial details of the transaction, which is expected to close later this year, have not been disclosed.
The report quotes “officials at the $301 billion Carlyle” as saying that the acquisition now allows Carlyle to operate across the life sciences and healthcare investment spectrum from venture capital to through to buyouts.
Read more: Private Equity Wire
